title: Neonatal epithelial hypoxia inducible factor-1α expression regulates the response of the lung to experimental asthma.
abstract: Allergic airway disease is characterized by a T helper type 2 cell-mediated airway inflammation and airway hyperresponsiveness. Little is known about the role of hypoxia-mediated signaling in the progression of the disease. To address this knowledge gap, a mouse model was created in which doxycycline exposure induces the functional deletion of hypoxia inducible factor-1α from alveolar type II and Clara cells of the lung. When hypoxia inducible factor-1α deletion was induced during the early postnatal development period of the lung, the mice displayed an enhanced response to the ovalbumin model of allergic airway disease. These hypoxia inducible factor-1α-deficient mice exhibit increased cellular infiltrates, eosinophilia in the lavage fluid and parenchyma, and T helper type 2 cytokines, as compared with ovalbumin-treated control mice. Moreover, these hypoxia inducible factor-1α-deficient mice display increased airway resistance when compared with their control counterparts. Interestingly, if the loss of hypoxia inducible factor-1α was induced in early adulthood, the exacerbated phenotype was not observed. Taken together, these results suggest that epithelial hypoxia inducible factor-1α plays an important role in establishing the innate immunity of the lung and epithelial-specific deficiency in the transcription factor, during early postnatal development, increases the severity of inflammation and functional airway resistance, following ovalbumin challenge. Finally, these results might explain some of the chronic respiratory pathology observed in premature infants, especially those that receive supplemental oxygen. This early hyperoxic exposure, from normal ambient and supplemental oxygen, would presumably inhibit normal hypoxia inducible factor-1α signaling, mimicking the functional deletion described.
authors.affiliation: Department of Biochemistry and Molecular Biology, Michigan State University, East Lansing, Michigan 48824, USA.
authors.forename: Krista K
authors.initials: KK
authors.lastname: Greenwood
authors.forename: Steven P
authors.initials: SP
authors.lastname: Proper
authors.forename: Yogesh
authors.initials: Y
authors.lastname: Saini
authors.forename: Lori A
authors.initials: LA
authors.lastname: Bramble
authors.forename: Daven N
authors.initials: DN
authors.lastname: Jackson-Humbles
authors.forename: James G
authors.initials: JG
authors.lastname: Wagner
authors.forename: Jack R
authors.initials: JR
authors.lastname: Harkema
authors.forename: John J
authors.initials: JJ
authors.lastname: LaPres
mesh_terms: D000403:Airway Resistance / Q000187:drug effects; D000818:Animals; D000831:Animals, Newborn; D001249:Asthma / Q000139:chemically induced / Q000276:immunology / Q000378:metabolism*; D001992:Bronchoalveolar Lavage Fluid / Q000737:chemistry; D016085:Bronchoconstrictor Agents / Q000494:pharmacology; D002452:Cell Count; D016207:Cytokines / Q000378:metabolism; D047093:Eosinophil Major Basic Protein / Q000378:metabolism; D004804:Eosinophils / Q000378:metabolism / Q000473:pathology; D005260:Female; D015870:Gene Expression; D005786:Gene Expression Regulation; D051795:Hypoxia-Inducible Factor 1, alpha Subunit / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*; D007113:Immunity, Innate; D007249:Inflammation / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D008168:Lung / Q000378:metabolism* / Q000473:pathology; D016210:Methacholine Chloride / Q000494:pharmacology; D051379:Mice; D008822:Mice, Transgenic; D010047:Ovalbumin; D011897:Random Allocation
chemical_list: D016085:Bronchoconstrictor Agents; D016207:Cytokines; C497443:Hif1a protein, mouse; D051795:Hypoxia-Inducible Factor 1, alpha Subunit; D016210:Methacholine Chloride; D010047:Ovalbumin; D047093:Eosinophil Major Basic Protein